CINECA IRIS Institutional Research Information System

PIPPIONE, Agnese Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.379
EU - Europa 2.333
AS - Asia 951
AF - Africa 45
SA - Sud America 35
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.758
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.264
IT - Italia 854
IE - Irlanda 329
CN - Cina 322
SE - Svezia 245
DE - Germania 189
SG - Singapore 186
FR - Francia 150
GB - Regno Unito 122
IN - India 111
CA - Canada 104
AT - Austria 103
UA - Ucraina 82
VN - Vietnam 65
HK - Hong Kong 55
FI - Finlandia 53
JP - Giappone 44
KR - Corea 37
BE - Belgio 35
DK - Danimarca 31
IR - Iran 28
PL - Polonia 25
TW - Taiwan 25
NL - Olanda 24
BR - Brasile 18
CZ - Repubblica Ceca 16
NG - Nigeria 15
TR - Turchia 14
AU - Australia 13
PK - Pakistan 13
CH - Svizzera 12
ID - Indonesia 12
SN - Senegal 12
MY - Malesia 11
PT - Portogallo 11
ES - Italia 10
AR - Argentina 7
GR - Grecia 6
IQ - Iraq 6
ZA - Sudafrica 6
BG - Bulgaria 5
BZ - Belize 5
CO - Colombia 5
MX - Messico 5
RS - Serbia 5
RU - Federazione Russa 5
SA - Arabia Saudita 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
CI - Costa d'Avorio 4
CL - Cile 4
HR - Croazia 4
MA - Marocco 4
NO - Norvegia 4
UZ - Uzbekistan 4
PH - Filippine 3
EG - Egitto 2
EU - Europa 2
GE - Georgia 2
GH - Ghana 2
HU - Ungheria 2
MK - Macedonia 2
RO - Romania 2
BD - Bangladesh 1
BO - Bolivia 1
CU - Cuba 1
EE - Estonia 1
IL - Israele 1
LV - Lettonia 1
SY - Repubblica araba siriana 1
Totale 6.758
Salva come PNG Salva come JPEG
Città #
Chandler 549
Dublin 322
Torino 184
Nyköping 148
Ann Arbor 146
Singapore 122
Turin 119
Los Angeles 116
Beijing 114
Ashburn 107
Houston 106
Vienna 103
Fairfield 99
Woodbridge 95
Jacksonville 93
Medford 86
Redwood City 77
Princeton 71
Wilmington 65
Villeurbanne 64
Dearborn 62
Fremont 56
Seattle 55
Milan 49
Cambridge 42
Dong Ket 41
Ottawa 40
Rome 36
Pisa 34
Brussels 32
Guangzhou 26
Santa Clara 24
Shanghai 23
Boston 21
Copenhagen 21
Nanjing 21
New York 21
Boardman 19
Québec 19
Warsaw 17
Toronto 16
Hangzhou 15
Munich 15
Washington 15
San Diego 14
Menlo Park 13
Viterbo 13
Abuja 12
Bradford 12
Paris 12
Piemonte 12
Central 11
Delhi 11
Naples 11
Tokyo 11
Ypsilanti 11
Ahmedabad 10
Hefei 10
Taipei 10
Bari 9
Chengdu 9
Jakarta 9
Rivoli 9
Taichung 9
Amsterdam 8
Buffalo 8
Gunzenhausen 8
Hebei 8
Helsinki 8
Jinan 8
Kuala Lumpur 8
Siena 8
Tai Wan 8
Alessandria 7
Birmingham 7
Leeds 7
Leinì 7
Lisbon 7
Norwalk 7
Novara 7
Pittsburgh 7
Riverside 7
Uppsala 7
Cassano Magnago 6
Chennai 6
Cleveland 6
Duncan 6
Epsom 6
Hamburg 6
Lappeenranta 6
Luzhou 6
Montreal 6
Mumbai 6
Philadelphia 6
Seongbuk-gu 6
Barcelona 5
Belize City 5
Bratislava 5
Catania 5
Durban 5
Totale 3.963
Salva come PNG Salva come JPEG
Nome #
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 340
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 276
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 244
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 225
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 186
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 167
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 167
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 155
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 154
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 151
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 150
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 139
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 135
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 121
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 113
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 112
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 111
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 109
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 106
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 106
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 103
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 102
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 97
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 93
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 91
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 88
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 87
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 84
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 83
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease 83
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 82
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 80
NEW HYDROXYAZOLES INHIBITORS OF AKR1C3 OBTAINED FROM NSAIDS BY SCAFFOLD HOPPING APPROACH AGAINST CASTRATE RESISTANT PROSTATE CANCER 80
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 80
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 75
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 72
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 71
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 71
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 67
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 66
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 65
Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans) 64
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 64
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 61
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 58
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 58
Synthesis of new Plasmodium Falciparum dihydroorotate dehydrogenase inhibitors through the application of an isosteric portfolio 57
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 56
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 54
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 52
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 48
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 48
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 48
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research 47
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 47
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 46
Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems 45
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 44
Synthesis, physiochemical proprieties and application of hydroxyazole systems as carboxylic acid isoster 41
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 41
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 41
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 41
Develop of new fluorescent probe to target hDHODH enzyme 40
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats 40
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 39
Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems 38
Antileishmanial activity of some 4-phenyl-3-amino-1H-pyrazols designed as CRK3 kinase inhibitors 38
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 36
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 34
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 33
Synthesis of [18F] Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 33
Improving the fluorescent profile of pyrazolo [1,5-a]pyridine fluorophores for developing new fluorescent probes 32
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 32
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 32
Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease 32
Toward a Bioisosteric Alkahest: Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 30
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 28
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 28
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 25
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 24
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 22
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 22
Effects of new hydroxyazoles inhibitors of AKR1C3 on vitality of prostate and colorectal cancer cell lines 21
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 20
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 16
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 16
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) 16
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 11
AI Based Discovery of a New AKR1C3 Inhibitor for Anticancer Applications 11
NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER 10
Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis 8
Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700 1
Totale 6.981
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.652
article - articoli 0
book - libri 0
conference - conferenze 14.753
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.405
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020644 0 0 25 76 39 98 113 42 57 75 70 49
2020/2021733 83 70 48 46 54 39 47 36 96 58 60 96
2021/20221.032 49 24 59 91 38 48 43 37 26 133 303 181
2022/20231.902 189 229 68 180 145 432 145 115 162 57 100 80
2023/20241.135 128 140 81 68 77 124 148 45 13 105 85 121
2024/2025252 72 180 0 0 0 0 0 0 0 0 0 0
Totale 6.981